Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Grb2-associated binding protein 2 (GAB2) is a scaffolding protein which contains diverse structural domains and docking sites that serve as a platform for the assembly of signaling systems. GAB2 is expressed ubiquitously, but it is most highly expressed in heart, brain, kidney, lung, testis, and ovary. Although GAB2 itself lacks enzymatic activity, it works downstream of receptor tyrosine kinases (RTK) and non-RTKs, such as cytokine, to transmit and amplify signals to downstream effectors. After stimulation, GAB2 becomes phosphorylated on critical tyrosine residues creating binding sites for diverse targets involved in signal transduction. Therefore, GAB2 acts as a mediator of essential cellular processes including proliferation, survival, differentiation, and migration.
Structure and function of Gab2
Gab2 is composed of a central praline‑rich domain (PRD), an N‑terminal Pleckstrin homology (PH) domain and multiple tyrosines within potential binding motifs, which are favored by diverse SH‑2 and 3 domain‑containing proteins. All three domains, especially the PH domain, are highly conserved in the process of organic evolution.
The N‑terminal PH domain’s binding to PIP3 is involved in membrane recruitment of Gab2. Prior reports have indicated that the PH domain could also be involved in regulating intracellular signaling (Fas‑signaling pathway), not just a localization module. The PRD contains numerous PXXP motifs, which mediate the interaction with SH3 domain‑containing proteins, including Grb2. There are various sites of tyrosine phosphorylation, which may interact with SH2 domain‑containing proteins, including p85 and SHP2. This interaction is significant for the function of Gab2 in mediating intracellular signaling pathways, which are important for normal cell growth, development, differentiation and apoptosis (Figure 1).
Figure 1. Schematic diagram of GAB2 signaling and GAB2 protein structure (Adams S J, et al., Molecular Cancer Research).
Gab2 and cancer
The DNA amplification is a common mechanism resulting in oncogenic activation in human cancer. GAB2 is located on chromosomal band 11q14.1. Amplification of 11q13-14.1 is often observed in human malignancies. The identification of GAB2 as a potential oncogene comes from studies in breast cancer, melanoma, leukemia, and ovarian cancer.
It was reported that the expression of Gab2 is reduced in invasive cancer and lymph node metastases, compared with ductal carcinoma in situ (DCIS), although it remains higher than in normal breast tissue. Overexpression of Gab2 in MCF‑10A cells, an immortalized and non‑transformed human mammary epithelial cell line, contributes to increased proliferation and alterations in dependency on EGF and other growth factors. By comparison, ablation of Gab2 in several breast cancer cell lines, inhibiting genomic amplifications, results in a decrease in proliferation, because of a reduction in cell‑cycle progression and increased apoptosis, and a reduction in their invasive potential. Overexpression of Gab2 in MCF‑10A cells promotes enhanced cell migration by modulating the activation of Ras homolog gene family, member A, which is dependent on the SHP2‑binding sites. Gab2 is required for efficient ErbB2‑driven mammary tumorigenesis and metastatic spread. Gab2 acts downstream of Neu, also termed HER2 and ErbB2, and is tyrosyl‑phosphorylated upon activation of signal transduction.
The development of melanoma is closely linked to oncogenic activation of ERK and PI3-K-AKT signaling. GAB2 scaffolding protein is crucial to the propagation of these signaling cascades and has been implicated as a driver of melanomagenesis. GAB2 is expressed at significantly higher levels in metastatic melanomas as compared with primary melanomas and melanocytic nevi, and thus can be seen as a marker of neoplastic progression. Silencing of GAB2 in metastatic melanoma cell lines results in a decrease in their invasive potential, whereas overexpression in primary melanomas promotes migration and invasion. Furthermore, in vivo studies show that overexpression of GAB2 results in enhanced tumor growth and development of metastases.
The first evidence for the pivotal contribution of Gab2 to leukemogenesis was an investigation, which indicated that myeloid progenitors from Gab2‑deficient mice are resistant to transformation by the BCR‑ABL oncoprotein. And the oncoprotein arises from a chromosomal translocation found in >90% of patients with chronic myeloid leukaemia (CML). The oncogenic protein tyrosine kinase, BCR‑ABL, interacts with Grb2 and Gab2 signaling, and triggers hematopoietic cell proliferation. In BCR/ABL‑positive CML bone marrow, Gab2‑positive myeloid cells are significantly more frequent, compared with normal bone marrow. These findings demonstrate that Gab2 is part of a protein complex that is important, if not essential, in BCR/ABL‑driven CML. Moreover, BCR‑ABL1 is not only present in CML patients, but also occurs in 20‑30% of patients with acute lymphoblastic leukemia (ALL). Therefore, these studies suggest that human CML could depend on BCR/ABL‑driven Gab2 signaling and identify Gab2 as a potential therapeutic target.
Genomic amplifications of Gab2 have been described in around 16% of ovarian carcinoma cases. The expression of Gab2 predominantly regulates the migratory behaviors of ovarian cancer cells, and overexpression of Gab2 enhances invasion and migration, and downregulates the expression of E‑cadherin in ovarian cancer cells with low baseline expression levels of Gab2. On the contrary, silencing of Gab2 inhibits the migration and invasion, and positively regulates E‑cadherin expression in ovarian cancer cells with high‑Gab2 expression. Moreover, Dunn GP et al identified that Gab2 as an ovarian cancer oncogene, which potently transforms immortalized ovarian and fallopian tube secretory epithelial cells via the activation of PI3K signaling. The novel Gab2/PI3K/Zeb1 pathway can be targeted by PI3K and mammalian target of rapamycin (mTOR) inhibitors and can be potentially used to treat Gab2‑driven ovarian cancer combined with standard chemotherapy.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.